STOCK MARKETS

Argenx to acquire biotech firm Unnatural Products for $1.15 billion

By Investing.com2 min readInvesting.com
Argenx to acquire biotech firm Unnatural Products for $1.15 billionArgenx to acquire biotech firm Unnatural Products for $1.15 billion

 Argenx SE announced Monday it will acquire biotech firm Unnatural Products for $550 million upfront plus contingent value rights tied to development and regulatory milestones, bringing the total potential value to approximately $1.15 billion.

The acquisition builds on a two-year multi-target research collaboration between the companies. Unnatural Products, a biotech company developing orally-delivered macrocyclic peptides, will continue operating from its Santa Cruz, California site as part of argenx’s global research organization following the transaction.

The deal is expected to close by year-end, subject to customary closing conditions. 

"Today is a tremendous milestone for UNP and a testament to the exceptional work of our scientists, employees, collaborators and supporters," said Cameron Pye, chief executive officer and co-founder of Unnatural Products. "From the earliest days, we believed our platform had the potential to redefine what is possible in the discovery and design of new medicines."

Karen Massey, chief executive officer of Argenx, said the acquisition adds macrocyclic peptide capabilities that complement the company’s antibody engineering. "After working together for more than two years, we also know there is a strong fit in how we work: science first, entrepreneurial and focused on patients," Massey said.

Macrocyclic peptides combine the precision of biologics with oral dosing convenience and can reach intracellular targets that conventional drugs cannot access. Unnatural Products has built a discovery platform that pairs AI-guided design with parallel synthesis and direct-to-biology screening.